KR20030078105A - The novel composition of excipient for solid dosage form - Google Patents

The novel composition of excipient for solid dosage form Download PDF

Info

Publication number
KR20030078105A
KR20030078105A KR1020020016923A KR20020016923A KR20030078105A KR 20030078105 A KR20030078105 A KR 20030078105A KR 1020020016923 A KR1020020016923 A KR 1020020016923A KR 20020016923 A KR20020016923 A KR 20020016923A KR 20030078105 A KR20030078105 A KR 20030078105A
Authority
KR
South Korea
Prior art keywords
excipient
direct
tableting
lactose
starch
Prior art date
Application number
KR1020020016923A
Other languages
Korean (ko)
Inventor
김학형
박병호
민경준
안은경
최미선
오윤옥
Original Assignee
(주)다산메디켐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)다산메디켐 filed Critical (주)다산메디켐
Priority to KR1020020016923A priority Critical patent/KR20030078105A/en
Publication of KR20030078105A publication Critical patent/KR20030078105A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE: A novel composition of the dilutant for direct tableting for a solid formulation is provided which improves the fluidity of powder and prevents viscosity while tableting. Therefore, it is useful in the field of pharmaceutical industry. CONSTITUTION: A novel composition of the dilutant for direct tableting for a solid formulation is characterized by containing 80-96% of lactose, and 6-14% of starch and using 1-10% of a water-soluble polymer as a linking agent.

Description

제약 및 식품산업의 정제 제조시 반드시 거쳐야 하는 공정인 타정(정제의 제조) 공정에서 타정을 위한 분체 혼합물의 유동성을 개선하고 타정 공정시 발생되는 타정장애 중 특히 타정물이 타정기 또는 타정펀치에 붙든 현상인 점착성 발생을 없앤 제약산업에서 사용될 수 있는 고형제제를 위한 직타용 부형제의 새로운 조성물에 관한것이다.{The novel composition of excipient for solid dosage form}Improvement of the fluidity of the powder mixture for tableting in the tableting process, which is an essential step in the manufacturing of tablets in the pharmaceutical and food industries, and among tableting disorders caused by the tableting process, especially tablets stuck to tableting machines or tablet punches. The novel composition of excipients for solid dosage forms for solid preparations that can be used in the pharmaceutical industry without the occurrence of phosphorous adhesion.

미결정셀룰로오스나 분말화된 셀룰로오스, 전분, 유당, 디칼슘포스페이트 그리고 소르비톨 등이 제약 및 식품산업에서 내용고형제 제조를 위하여 부형제로 광범위하게 사용된다. 이러한 내용고형제를 위한 부형제는 타정혼합물의 흐름성, 주성분과의 혼합성, 정제 제조시의 타정성 그리고 빠른 붕해성, 타정펀치의 표면에 분말이 부착하여 정제 표면에 흠이 생기는 현상인 스틱킹(sticking), 정제의 상부가 모자 모양으로 박리되는 현상인 캡핑(capping), 정제가 증상으로 박리되는 현상인 라미네이팅(laminating)등과 같은 타정장애가 없어야 하며, 또한 적당한 정제의 경도와 빠른 붕해시간과 같은 상반되는 조건을 충족해야 하는 등 여러가지 조건에 적합하여야 한다. 이러한 예로는 제제학적으로 좋은 분체의 흐름성(유동성), 정제제조시 타정기의 낮은 압력 적용으로 얻어지는 정제의 좋은 타정성, 충분한 정제의 경도, 정제의 코팅 공정 및 유통시 이동중 포장상태에서의 외부 충격에 대한 낮은 마손도 및 마모도, 제조후 장기보관 또는 유통시 제품의 성상에 변화가 일어나지 말아야 되고 신속한 붕해 특히 고속 타정시 타정기의 디스크(타정혼합물이 접촉되는 판)와 타정펀치에 정제의 표면이 점착되어지는 스티킹 현상이 없어야 되는 등 많은 조건에 적합되어야 한다. 이러한 다양한 조건들은 시중의 부형제 특히 직타용 보조제에 의해 다소간 해소될 수 있다. 통상적으로 여기에 활택제, 결합제, 정제의 붕해를 촉진시키는 붕해제등이 추가적인 보조제가 타정를 위한 혼합물 제조시 더해진다. 일반적으로 유당, 셀룰로오스류, 전분류, 무기염류 등의 부형제를 타정 공정을 위한 부형제로 사용할 때 부형제와 주성분을 혼합하고 필요한 경우 불용성의 카르복시메칠셀룰로오스 칼슘염, 크로스링크된 카르복시메칠셀룰로오스, 크로스링크된 폴리비닐피롤리돈 또는 크로스링크된 카르복시메칠스타치 등과 같은 붕해제와 히드록시프로필셀룰로오스, 히드록시에칠셀룰로오스, 폴리비닐피롤리돈, 메칠셀룰로오스, 에칠셀룰로오스, 전분류, 젤라틴 등과 같은 수용액 또는 제약산업에 허용되는 유기용매에 용해되는 결합제와 같이 혼합하고 이때 함께 혼재되는 혼합물, 연합물 및 과립물을 건조시키고 활택제를 추가 혼합한 후 정제로 타정하는 생산공정을 사용한다. 이러한 통상적인 습식의 제조방법으로도 훌륭한 타정용 과립물을 얻을 수 있으나, 상기의 조건을 충족시키기가 어렵고, 이러한 방법은 공정이 복잡하고 작업인원이 과다하게 많이 필요하며 유기용매를 사용하기도 하여야 한다. 또한 이러한 제조 방법은 제제학적 제제공정상의 문제점이 종종 나타난다. 예를 들면 주성분이 열, 수분, 유기용매에 불안정을 초래할 수 있고, 물리화학적 성질의 변화를 초래하여 결정성의 변화 및 주성분의 용해, 용융이 발생되어 타정장애 또는 용출률의 변화와 생체이용률의 변화가 야기될 수 있다. 이러한 상기의 조건을 충족시키고 주성분과 혼합한 후에 직접 정제를 생산할 수 있게 하며 또한 직타용 부형제의 양을 최소화하는 직타용 보조제를 제공하는것이 본 발명의 목적이다.Microcrystalline cellulose or powdered cellulose, starch, lactose, dicalcium phosphate and sorbitol are widely used as excipients for the manufacture of internal solids in the pharmaceutical and food industries. Such excipients for internal solids are sticking, which is a phenomenon in which tablets adhere to the surface of tablets due to the flowability of tableting mixtures, mixing with the main components, tableting properties and rapid disintegration during tablet manufacturing, and the surface of tablets. there should be no tableting disorders such as sticking, capping where the upper part of the tablet is peeled off like a hat, laminating when the tablet is peeling off as a symptom, and also suitable tablet hardness and fast disintegration time. It should be suitable for various conditions, such as the conflicting conditions must be met. Examples include pharmaceutical formulations with good flowability (liquidity), good tableting properties obtained by low pressure application of tableting machines during tablet manufacturing, sufficient tablet hardness, external coating impact during tablet coating, and packaging during transport. Low abrasion and abrasion resistance, no change in product properties during long-term storage or distribution after manufacture, and the surface of the tablet adheres to the tablets (plates in contact with the tableting mixture) and tableting punches during rapid disintegration, especially at high-speed tableting It should be suitable for many conditions such that there should be no sticking phenomenon. These various conditions can be somewhat resolved by commercial excipients, in particular direct aids. Typically, lubricants, binders, disintegrating agents that promote disintegration of tablets, and the like are added to the auxiliary adjuvant when preparing the mixture for tableting. In general, when excipients such as lactose, cellulose, starch, inorganic salts are used as excipients for the tableting process, the excipients and the main ingredients are mixed and, if necessary, insoluble carboxymethylcellulose calcium salt, crosslinked carboxymethylcellulose, crosslinked Disintegrants such as polyvinylpyrrolidone or crosslinked carboxymethyl starch, and aqueous solutions or pharmaceuticals such as hydroxypropylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, methylcellulose, ethylcellulose, starch, gelatin, etc. A production process is used that mixes with binders dissolved in an organic solvent acceptable to the industry, wherein the mixtures, associations and granules mixed together are dried, further mixed with lubricant and compressed into tablets. Although such a conventional wet preparation method can provide excellent tableting granules, it is difficult to satisfy the above conditions, and this method has a complicated process, requires a large number of workers, and requires use of an organic solvent. . In addition, these preparation methods often show problems in the formulation process. For example, the main component may cause instability in heat, moisture, and organic solvents, and may cause changes in physicochemical properties, resulting in changes in crystallinity, dissolution and melting of the main component, resulting in tableting disorders or changes in dissolution rate and bioavailability. May be caused. It is an object of the present invention to provide a tablet for the tablets which meets the above conditions and makes it possible to produce tablets directly after mixing with the main ingredient, and also minimizes the amount of the tablet for the tablets.

제약 및 식품산업의 내용고형제의 제조방법을 단순화, 안정화, 안전화하게 하여 제품 품질의 향상과 제조 공정 단축에 의한 제조 원가 감소를 목적으로 하고 본 발명이 의도하는 각각의 의약조성물을 조합하여 신규 직타용 조성물을 제조하고 내용 고형제 특히 정제 제조시 통상의 습식 과립 제조 방법을 하지 않고 주성분과 부형제를 혼합 후 직타할 수 있는 직타용 부형제를 제조하여 기존 직타용부형제의 주요 문제점인 고함량의 주성분과 혼합시 발생되는 흐름성(유동성) 및 정제의 부착현상 (Sticking) 방지를 해결하고자 본 발명을 하게 되었다.It aims to improve the product quality and reduce the manufacturing cost by shortening the manufacturing process by simplifying, stabilizing and securing the manufacturing method of the solids in the pharmaceutical and food industries, and combining the pharmaceutical compositions intended by the present invention. To prepare other compositions and to prepare the content solids, especially tablets, without the usual wet granules manufacturing method, by preparing a direct excipient that can be directly driven after mixing the main component and excipients, the high content of the main component of the conventional direct excipient The present invention has been made to solve the flowability (fluidity) and the sticking phenomenon (Sticking) of the tablet generated when mixing.

본 발명자들은 발명의 목적을 본 발명에 따른, 다음의 세가지 성분이 잘 섞여있는 혼합물로 구성된 직타용 부형제에 의해 구현되는것을 알게 되었다.The inventors have found that the object of the invention is embodied in accordance with the invention by means of excipients for direct hits, which are composed of a mixture of the following three components.

1) 유당을 전체 조성물에 대하여 중량비로 80 ∼ 96 %의 정제에 제제학적으로 적합한 고운 분말의 담체와 2) K 값이 25, 30, 60, 90인 폴리비닐피롤리돈(포비돈 K 25, K 30, K 60, K 90 F) ,히드록시프로필셀룰로오스, 히드록시에칠셀룰로오스, 히드록시프로필메칠셀룰로오스, 메칠셀룰로오스, 에칠셀룰로오스, 젤라틴, 호화전분과 같은 결합제중 1종 또는 1종이상의 혼합물을 선택하여 중량비로 1 내지 10 %를 함유하는 결합제와 3) 물 또는 인공 1, 2액에서 붕괴하는 전분를 선택하여 중량비로 6 ∼ 14 %의 붕해제로 구성됨을 특징으로 하는것이다. 본 발명의 바람직한 실시예에서 600 마이크로미터 이하의 입자크기의 유당 자체를 기제로 사용된다. 그러나 분말 셀룰로오스가 사용될 수 있고, 물론 유당과 분말 셀룰로오스, 유당과 만니톨, 유당과 칼슘포스페이트, 분말 셀룰로오스와 만니톨, 유당과 전분 또는 분말 셀룰로오스와 칼슘포스페이트의 혼합물도 사용될 수 있다. 세가지 성분 (1), (2), (3)의 잘 섞여진 혼합물은 건식과립이나 습식과립 또는 분무 건조법이나 유동층 조립법과 같은 제제학적으로 허용되는 방법으로 제조할 수 있다. 유동층 조립법 공정은 예를 들면 다음과 같이 할 수 있다 ; 유당 또는 상기에서 언급한 제제학적으로 허용하는 의약 부형제와 (3) 성분의 혼합물을 먼저 유동층 과립기 컨테이너에 투입하고 챔버내에서 분말 혼합물을 유동시키면서 흡입되는 공기의 온도를 40 ∼ 80 ℃로 가온하면서 (2) 성분의 용해된 용액으로 분무를 하여 목적된 건조 과립물을 얻을 수 있다. 일반적인 습식 과립법 중 바스킷이나 체망을 통한 압출식 조립법 과 고속 회전 조립 공정 또는 리본형혼합기를 이용한 제립방식으로 다음과 같이 제조할 수 있다 ; 유당 또는 상기에서 언급한 제제학적으로 허용하는 의약 부형제와 (3) 성분과 미리 혼합하고 (2) 성분이 용해된 용액을 균질하게 혼합 교반하면서 투입한다. 그리고 습윤되어 있는 상태의 혼합물을 바스킷망이나 체망을 통과시키고 건조하여 과립물을 얻는다. 또한 분무건조 공정으로 하여 일정한 건조과립을 얻을 수 있다; 각각의 성분이 일정량씩 용해 또는 현탁되어 있는 현탁 용액이 적절한 분무기에서, 예를 들면 흡입온도가 최대 섭씨 120 ℃의 건조 공기의 순방향이나 역방향으로 분사된다. 특정한 분무건조과정에서 미세입자의 유당 분말로 부터 출발하여 일정한 좁은 범위의 입도 분포를 갖는 예를 들면 60 ∼ 70 % 의 100 ∼ 250 마이크로미터의 입자가 대략 50 ∼ 500 마이크로미터의 입도 분포에 포함되는 조립물을 얻게된다. 다음의 실시예는 본 발명의 신규 직타용 부형제를 위한 혼합물 제조에 관한 조성물과 다른 직타용 부형제를 이용한 타정시험과 신규 직타용 부형제 조성물과 시판 직타용 부형제를 이용하여 종합비타민제(특히 토코페롤을 함유하는)와 혼합하여 혼합물에 관한 제제학적 시험을 한 실시예 및 시험예이며 이것이 전체의 발명을 한정 짓는것은 아니다.1) a carrier of fine powder pharmaceutically acceptable for tablets of 80 to 96% by weight of the total composition, and 2) polyvinylpyrrolidone (povidone K 25, K having K values of 25, 30, 60, 90). 30, K 60, K 90 F), hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, gelatin, one or more kinds of mixtures such as gelatin starch It is characterized in that it comprises a binder containing 1 to 10% by weight and 3) starch disintegrating in water or artificial 1, 2 liquid by weight 6 to 14% disintegrant by weight. In a preferred embodiment of the present invention, lactose of particle size of 600 micrometers or less is used as the base. However, powdered cellulose may be used, and of course lactose and powdered cellulose, lactose and mannitol, lactose and calcium phosphate, powdered cellulose and mannitol, lactose and starch or mixtures of powdered cellulose and calcium phosphate may also be used. Well mixed mixtures of the three components (1), (2) and (3) can be prepared by pharmaceutically acceptable methods such as dry granules, wet granules or spray drying or fluid bed granulation. The fluidized bed granulation step may be, for example, as follows; The mixture of lactose or the above-mentioned pharmaceutically acceptable excipient and (3) component is first introduced into a fluidized bed granulator container, while the powder mixture is flowed in the chamber while the temperature of the air sucked is warmed to 40 to 80 ° C. The desired dry granules can be obtained by spraying with a dissolved solution of component (2). Among the general wet granulation methods, extrusion granulation through a basket or sieve and high speed rotary granulation or granulation using a ribbon type mixer can be produced as follows; Lactose or the pharmaceutically acceptable pharmaceutical excipients mentioned above are premixed with component (3) and the solution in which component (2) is dissolved is added with homogeneous mixing and stirring. The wetted mixture is then passed through a basket or sieve and dried to obtain granules. It is also possible to obtain a constant dry granule by the spray drying process; Suspension solutions in which each component is dissolved or suspended by a certain amount are sprayed in a suitable nebulizer, for example, in the forward or reverse direction of dry air with a suction temperature of up to 120 degrees Celsius. In a particular spray drying process, for example, 60 to 70% of particles of 100 to 250 micrometers having a narrow particle size distribution starting from the microparticle lactose powder are included in the particle size distribution of approximately 50 to 500 micrometers. You get an assembly. The following example shows the synthesis of a mixture for the novel direct excipient of the present invention, a tableting test using other excipients, and a new vitamin direct excipient composition and a commercial direct excipient using a multivitamin (particularly containing tocopherols). ) Is an example and a test example for the formulation test of the mixture, which does not limit the whole invention.

실시예 1) 유당 88 %Example 1) Lactose 88%

전분 10 %Starch 10%

폴리비닐피롤리돈 K 90 2 %Polyvinylpyrrolidone K 90 2%

실시예 2) 유당 88 %Example 2) Lactose 88%

전분 12 %Starch 12%

실시예 3) 유당 86 %Example 3) Lactose 86%

전분 10 %Starch 10%

히드록시프로필셀룰로오스 4 %Hydroxypropylcellulose 4%

실시예 4) 유당 82 %Example 4 Lactose 82%

전분 10 %Starch 10%

젤라틴 8 %Gelatin 8%

상기의 혼합물은 다음의 과정에 의해 타정용 혼합물로 제조될 수 있다. 유동층 조립법으로 유당과 붕해제를 유동층 과립기 쳄버에서 혼합시키면서 물에 용해된 결합제를 분사하여 과립물을 건조하면서 제조한다. 이 방법외에 바스킷 망 또는 체망을 사용하는 수평식 연합기(kneader) 또는 압출식 재래식에서는 유당과 붕해제를 함께 섞는다. 결합제를 물에 녹여 유당과 전분의 혼합 분산물에 투입하고 습윤된 혼합물을 0.88 밀리미터 체를 통과시킨다. 이 습윤된 과립물을 40 ℃에서 건조하고 그 다음 0.55 밀리미터 체를 이용하여 입자를 균일하게 만든다. 다른 방법으로는 유당과 전분의 혼합분산물에 용해된 결합제의 용액을 투입하고 혼합 및 연합을 하여 유동층 건조기 또는 열풍 건조기에서 건조감량(105 ℃, 20분) 2 % 이하로 건조시키고 0.55 밀리미터 체를 이용하여 정립하여 입자를 균리하게 만든다.The mixture may be prepared into a tableting mixture by the following procedure. Lactose and disintegrant are mixed in a fluidized bed granulator chamber by a fluid bed granulation method, and the granules are dried by spraying a binder dissolved in water. In addition to this method, lactose and disintegrants are mixed together in horizontal kneaders or extruded conventionals using basket or sieve nets. The binder is dissolved in water and poured into a mixed dispersion of lactose and starch and the wet mixture is passed through a 0.88 millimeter sieve. This wet granule is dried at 40 ° C. and then uniformized using a 0.55 millimeter sieve. Alternatively, a solution of the binder dissolved in a mixed dispersion of lactose and starch is added, mixed and coalesced, dried to 2% or less in a fluidized bed dryer or hot air dryer (105 ° C., 20 minutes), and the 0.55 mm sieve is removed. Sizing to make particles uniform.

시험예 1) 유동성 시험 : 분체 유동성 측정기(직경 5 밀리미터, slope 30°)를 이용하여 분체의 흐름성을 측정하였다.Test Example 1) Flowability Test: The flowability of the powder was measured using a powder flow meter (diameter 5 mm, slope 30 °).

표 1) 분체의 흐름성Table 1) Flowability of powder

실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 Ludipress® Ludipress ® 유동성(g/sec)Fluidity (g / sec) 2.52.5 5.65.6 44 55 66

시험예 2) 실시예 (2)의 입도 분포는 다음과 같다.Test Example 2 The particle size distribution of Example (2) is as follows.

595 ∼ 297 마이크로미터 : 32 % 미만595-297 micrometers: less than 32%

297 ∼ 210 마이크로미터 : 30 ∼ 35 %297 to 210 micrometers: 30 to 35%

210 ∼ 149 마이크로미터 : 22 ∼ 27 %210 to 149 micrometers: 22 to 27%

149 ∼ 105 마이크로미터 : 12 ∼ 17 %149 to 105 micrometers: 12 to 17%

시험예 3) 점착성(스틱킹) 발생 확인 위한 타정시험Test Example 3) A tableting test to confirm the occurrence of stickiness (sticking)

또한 시판품인 루디프레스®(Ludipress®) 와 실시예 (1) 방법에 의한 혼합물을 이용하여 활택제 성분 및 주성분으로 종합비타민(비타민 B1및 그의 염류, 비타민 B2및 그의 염류, 비타민 B6및 그의 염류, 비타민 E 및 그의 염류와 흡착물 등) 등이 함유하도록 혼합하여 로타리 타정기를 이용하여 평균 타정 중량 530 ± 30 밀리그람, 평균 경도 10 ±3 kg 으로 타정하고 이들의 붕해 시간, 마손도 및 점착여부(스틱킹)을 관찰 및 측정하였다.In addition, commercially available products of Rudy press ® (Ludipress ®) as in Example 1 in the lubricant component and the main component by using the mixture according to the method multivitamin (vitamin B 1 and their salts, vitamin B 2 and its salts, vitamin B 6, and Its salt, vitamin E and its salts and adsorbates, etc.), and tableted with a rotary tableting machine with an average tableting weight of 530 ± 30 milligrams and an average hardness of 10 ± 3 kg. Whether or not (sticking) was observed and measured.

처방Prescription

염산 치아민 --------------- 10.00 %Chiamine Hydrochloride --------------- 10.00%

낙산리보플라빈 ------------ 0.51 %Naksan Riboflavin ------------ 0.51%

인산 피리독살 -------------- 0.69 %Phosphoric Acid Pyridoxal -------------- 0.69%

초산 토코페롤 50% 흡착물 --- 8.00 %Tocopherol Acetate 50% Adsorbate --- 8.00%

실시예 1) ----------------- 62.04 %Example 1) ----------------- 62.04%

활택제 -------------------- 1.94 %Glidant -------------------- 1.94%

표 2) 시판품과의 타정 시험 결과Table 2) Tableting test result with commercial item

실시예 (1)Example (1) Ludipress® Ludipress ® 평균경도(kp)Average hardness (kp) 7 ~ 137 to 13 7 ~ 137 to 13 평균타정중량(mg)Average tablet weight (mg) 540540 540540 붕해시간(분)Disintegration time (minutes) 6 ∼ 86 to 8 6 ∼ 86 to 8 점착발생여부Adhesion XX 타정개시 후 3-5분경과 후 발생Occurs after 3-5 minutes after tableting 마손도(%)Wear and tear (%) 0.01 이하0.01 or less 0.01 이하0.01 or less

이러한 신규 조립물은 낮은 압력에서의 좋은 타정성, 타정시 정제의 높은 경도와 낮은 마손도/마모도 및 신속한 붕해력을 갖게 되어 기존의 직타용 부형제 보다 훨씬 더 좋은 직타용 부형제의 성질을 갖는다. 전분과 유당 또는 기타의 수불용성의 부형제을 습식과립 제조방법으로 폴리비닐피롤리돈, 히드록시프로필셀룰로오스, 변성전분, 폴리비닐알코올등과 같은 결합제의 용액을 분무 또는 투입하고 건조 후 타정하는것에 비하여 신규의 직타용 부형제를 미리 제조하고 그리고 주성분과 혼합하여 직타를 수행하는것은 정제 제조업자에게 공정을 줄이는것 뿐만 아니라 물성면에서도 유리한 점이 있어서, 가장 문제가 되었던 정제의 부착성 문제 즉 스틱킹을 방지할 수 있는 상당히 개선된 부형제로 제공되며, 신속한 정제의 붕해시간과 타정 공정의 개선된 작업성면에서 놀랄만한 좋은 결과를 얻을 수 있다.These new granules have the properties of good tableting at low pressures, high hardness and low wear / wear and rapid disintegration of tablets during tableting, which are much better than conventional tableting excipients. Starch and lactose or other water-insoluble excipients are prepared by wet granulation, compared to spraying or adding a solution of a binder such as polyvinylpyrrolidone, hydroxypropyl cellulose, modified starch, polyvinyl alcohol, etc. Preparation and direct preparation of the excipients for direct use of tablets is advantageous not only to reduce the process but also to the physical properties of the tablet manufacturer, which prevents sticking problems, ie sticking, of the most problematic tablets. It is available in significantly improved excipients, and surprisingly good results can be obtained in terms of rapid disintegration time of tablets and improved workability of the tableting process.

Claims (7)

제제학적으로 허용되는 부형제로서 유당, 전분을 함유하고 수용성고분자물질을 결합제로 하여 제약 또는 식품 산업에서 고형제제를 생산하기 위하여 제공되어지는 직타용 부형제 조성물에 관한 것Pharmaceutically acceptable excipients comprising lactose, starch, and water-soluble polymers as binders for the preparation of direct excipient compositions for the production of solid preparations in the pharmaceutical or food industry 1항에 있어서 부형제로서 유당을 80 ∼ 96 % 를 함유하는것을 특징으로 하는 직타용 부형제 조성물The excipient composition for direct stroke according to claim 1, which contains 80 to 96% of lactose as an excipient. 1항에 있어서 부형제로서 전분을 6 ∼ 14 % 를 함유하는것을 특징으로 하는 직타용 부형제 조성물The excipient composition for direct rudder according to claim 1, which contains 6 to 14% of starch as an excipient. 1항에 있어서 수용성 또는 수팽윤성 고분자물질의 결합제로서 폴리비닐피롤리돈, 히드록시프로필셀룰로오스, 히드록시프로필메칠셀룰로오스, 호화전분, 젤라틴, 폴리비닐알코올, 메칠셀룰로오스, 에칠셀룰로오스, 히드록시에칠셀룰로오스와 같이 수용성 또는 수팽윤성 성질을 갖는 고분자물질를 1종 또는 이들 고분자물질을 1종이상 혼합하여 사용하는 결합제로 제조되는 직타용 부형제 조성물Polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, gelatinized starch, gelatin, polyvinyl alcohol, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose as binders of water-soluble or water-swellable polymers Excipient composition for direct hitting is prepared from a binder that uses a mixture of one or more polymer materials having water-soluble or water swellable properties, such as 1항에 있어서 사용되는 결합제의 양은 1 ~ 10% 를 함유하는것을 특징으로 하는 직타용 부형제 조성물The amount of the binder used in claim 1 is an excipient composition for direct hits, characterized in that it contains 1 to 10%. 1항에 의하여 제조된 직타용 부형제의 입자 크기가 50 ~ 500 마이크로미터가 되도록 제조된 직타용 부형제 조성물Direct excipient composition prepared so as to have a particle size of 50 to 500 micrometers of the direct excipient prepared according to claim 1 1항에 의하여 제조된 조성물이 의약품 또는 식품의 고형제제 생산시 사용될 수 있는 부형제 조성물Excipient compositions wherein the composition prepared according to claim 1 may be used in the production of solid preparations of pharmaceuticals or foods
KR1020020016923A 2002-03-28 2002-03-28 The novel composition of excipient for solid dosage form KR20030078105A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020020016923A KR20030078105A (en) 2002-03-28 2002-03-28 The novel composition of excipient for solid dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020020016923A KR20030078105A (en) 2002-03-28 2002-03-28 The novel composition of excipient for solid dosage form

Publications (1)

Publication Number Publication Date
KR20030078105A true KR20030078105A (en) 2003-10-08

Family

ID=32376931

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020016923A KR20030078105A (en) 2002-03-28 2002-03-28 The novel composition of excipient for solid dosage form

Country Status (1)

Country Link
KR (1) KR20030078105A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113388341A (en) * 2021-06-17 2021-09-14 安徽精公检测检验中心有限公司 Solid binder and preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006345A (en) * 1985-02-16 1991-04-09 Basf Aktiengesellschaft Direct tableting auxiliary
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
KR100226386B1 (en) * 1990-11-15 1999-10-15 요시카주 니시데 Direct compression method for preparing pills having cephalosporanic acid derivatives
KR20010107754A (en) * 2000-05-26 2001-12-07 민경윤 Process for preparing rapidly disintegrating tablet for oral administration
KR20010114199A (en) * 2001-12-11 2001-12-29 유형선 Novel pharmaceutical composition
US6358526B1 (en) * 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006345A (en) * 1985-02-16 1991-04-09 Basf Aktiengesellschaft Direct tableting auxiliary
KR100226386B1 (en) * 1990-11-15 1999-10-15 요시카주 니시데 Direct compression method for preparing pills having cephalosporanic acid derivatives
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
KR20010107754A (en) * 2000-05-26 2001-12-07 민경윤 Process for preparing rapidly disintegrating tablet for oral administration
US6358526B1 (en) * 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
KR20010114199A (en) * 2001-12-11 2001-12-29 유형선 Novel pharmaceutical composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113388341A (en) * 2021-06-17 2021-09-14 安徽精公检测检验中心有限公司 Solid binder and preparation method and application thereof
CN113388341B (en) * 2021-06-17 2023-09-15 安徽精公检测检验中心有限公司 Solid binder and preparation method and application thereof

Similar Documents

Publication Publication Date Title
US5006345A (en) Direct tableting auxiliary
EP3090730B9 (en) Tablets comprising eltrombopag olamine
EP0377658B1 (en) A free-flowing granular composition containing ibuprofen and a method for its preparation
CN101184489B (en) Pharmaceutical composition
US6294198B1 (en) Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
WO2010033179A1 (en) Granulates, process for preparing them and pharmaceutical products containing them
CN101404982A (en) Pharmaceutical formulation of aliphatic amine polymer and their preparation method
KR20110089180A (en) Directly compressible granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CN104080443A (en) Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose
CA3019508A1 (en) Oral preparation having exceptional elutability
KR20100121483A (en) Tablet having improved elution properties
EP1334732B1 (en) Pharmaceutical preparation of n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4 b]furan-8-yl)ethyl]propionamide coated with a copolyvidone-containing coating free of polyethylene glycol
US20170112768A1 (en) Directly compressible granular microcrystalline cellulose based excipient, manufacturing process and use thereof
KR20170128323A (en) Solid preparation containing colorant
EP0436373B1 (en) Process for making tablets containing spray-dried naproxen or naproxen sodium
KR20110086741A (en) Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
JP4293572B2 (en) Loxoprofen sodium-containing tablets
JP2006176496A (en) Solid agent and process for producing the same
KR20030078105A (en) The novel composition of excipient for solid dosage form
KR20200078561A (en) Pharmaceutical composition containing quinoline derivative
RU2377989C2 (en) Trimetazidine preparation as matrix tablet of prolonged action and method for making thereof
WO2017033115A1 (en) Stable pharmaceutical composition of alogliptin and metformin fixed dose combination
CN110354093A (en) A kind of mosapride citrate pharmaceutical composition
JP4591742B2 (en) Dioctylsodium sulfosuccinate-containing preparation and method for producing the same
KR20010114199A (en) Novel pharmaceutical composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application